Compare AbbVie Inc (ABBV) vs Public Storage (PSA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Public Storage — how do they compare? AbbVie Inc trades at $254.06 (market cap $449.91B), while Public Storage trades at $322.98 (market cap $57.71B). The key difference: AbbVie Inc is far larger — about 7.8× Public Storage's market cap, and Public Storage pays the higher dividend (3.65%). Which is the better fit depends on your goals.
| ABBV | PSA | |
|---|---|---|
Market Cap | $449.91B | $57.71B |
Sector | Health | Real Estate |
52-Week High | $261.07 | $329.64 |
52-Week Low | $184.85 | $258.44 |
Enterprise Value | $513.38B | $71.96B |
Dividend Yield | 2.72% | 3.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Public Storage (PSA) trades at $328.69, near analyst consensus targets, with a slight 0.29% dip. The stock shows strong technical momentum with bullish moving averages and support at $321. Fundamentally, PSA maintains robust profitability with a 39.16% net margin and consistent earnings beats, though valuation multiples like P/E of 33.47 appear elevated. Recent developments include a $1.2B Canadian acquisition and enhanced liquidity facilities, signaling growth initiatives.
Outlook remains positive driven by operational strength and strategic expansions, but risks include high valuation sensitivity and interest rate exposure. Analyst consensus leans Hold (62.86%), with a $330.38 price target suggesting limited near-term upside. Investors should weigh solid fundamentals against premium pricing in a normalized REIT environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →
